The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling

Journal of Clinical Investigation

Volumn 114, Issue 2, 2004, Pages 206-213

  Wang, Michael W H ^a   Wei, Shi ^a   Faccio, Roberta ^a   Takeshita, Sunao ^a   Tebas, Pablo ^a   Powderly, William G ^a   Teitelbaum, Steven L ^a   Ross, F Patrick ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C SRC ONCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDINAVIR; MEMBRANE LIPID; ONCOPROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PROTEIN KINASE B; PROTEINASE INHIBITOR; RITONAVIR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DEMINERALIZATION; BONE SPARING ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID RAFT; MOUSE; NONHUMAN; ONCOGENE SRC; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 4043065189     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI15797     Document Type: Article

References (37)

1. Manolagas, S.C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137.
2. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science. 289:1504-1508.
3. Suda, T., et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357.
4. Ross, F.P. 2000. RANKing the importance of measles virus in Paget's disease. J. Clin. Invest. 105:555-558.
5. Paton, N.I.J., Macallan, D.C., Griffin, G.E., and Pazianas, M. 1997. Bone mineral density in patients with human immunodeficiency virus infection. Calcif. Tissue Int. 61:30-32.
6. Tebas, P., et al. 2000. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 14:F63-F67.
7. Moore, A.L., et al. 2001. Reduced bone mineral density in HIV-positive individuals. AIDS. 15:1731-1733.
8. Brown, T., et al. 2002. Bone loss associated with abnormalities in glucose metabolism in HIV patients on protease inhibitors. In Programs and Abstracts of the Ninth Conference of Retroviruses and Opportunistic Infections. Seattle, Washington, USA. 314.
9. Arnsten, J.H., Freeman, R., Santoro, N., Kunins, H., and Schoenbaum, E.E. 2002. Bone mineral density and protease inhibitor use in older HIV-infected women. In Programs and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, USA. 314.
10. Wang, M.W., Wei, S., Teitelbaum, S.L., and Ross, F.P. 2001. The HIV protease inhibitor indinavir uniquely inhibits bone formation (abstract). J. Bone Miner. Res. 16(Suppl.):S372.
11. Teitelbaum, S.L., and Ross, F.P. 2003. Generic regulation of osteoclast development and function. Nat. Rev. Genet. 4:638-649.
12. Wei, S., Wang, M.W., Teitelbaum, S.L., and Ross, F.P. 2002. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and MAP kinase signaling. J. Biol. Chem. 21:6622-6630.
13. Yates, A.J.P., et al. 1988. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorprion, and bone metabolism in vivo and in vitro in rodents. J. Clin. Invest. 81:932-938.
14. Zhao, W.G., Byrne, M.H., Boyce, B.F., and Krane, S.M. 1999. Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J. Clin. Invest. 103:517-524.
15. Ma, Y.L., et al. 2001. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 142:4047-4054.
16. Franzoso, G., et al. 1997. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11:3482-3496.
17. Iorsova, V., et al. 1997. Osteoperrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3:1285-1289.
18. Wong, B.R., et al. 1999. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4:1041-1049.
19. Bruner, A., et al. 1999. Akr promotes cell survival by phosphorylaring and inhibiting a Forkhead transcription factor. Cell. 96:857-868.
20. Matsumoto, M., Sudo, T., Saito, T., Osada, A., and Tsujimoto, M. 2000. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J. Biol. Chem. 275:31155-31161.
21. Kobayashi, N., et al. 2001. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20:1271-1280.
22. Andre, P., et al. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. U. S. A. 95:13120-13124.
23. Schmidtke, G., et al. 1999. How an inhibitor of the HIV-I protease modulates proteasome activity. J. Biol. Chem. 274:35734-35740.
24. Miyazaki, T., et al. 2000. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J. Cell Biol. 148:333-342.
25. Lenhard, J.M., Weiel, J.E., Paulik, M.A., and Furfine, E.S. 2000. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. Biochem. Pharmacol. 59:1063-1068.
26. Phenix, B.N., Lum, J.J., Nie, Z., Sanchez-Dardon, J., and Badley, A.D. 2001. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood. 98:1078-1085.
27. Tsiodras, S., Mantzoros, C., Hammer, S., and Samore, M. 2000. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. 160:2050-2056.
28. Fellay, J., et al. 2001. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 358:1322-1327.
29. Liang, J.S., et al. 2001. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. 7:1327-1331.
30. Kelleher, A.D., Sewell, A.K., and Price, D.A. 2002. Dyslipidemia due to retroviral protease inhibitors. Nat. Med. 8:308.
31. Sturley, S.L., et al. 2002. Reply to "Dyslipidemia due to retroviral protease inhibitors". Nat. Med. 8:308-309.
32. McHugh, K.P., et al. 2000. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 105:433-440.
33. Wei, S., Wang, M.W.-H., Teitelbaum, S.L., and Ross, F.P. 2001. RANK ligand activates nuclear factor-κB in osteoclast precursors. Endocrinology. 142:1290-1295.
34. Simonet, W.S., et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309-319.
35. Feng, X., et al. 2001. A Glanzmann's mutation of the β3 integrin gene specifically impairs osteoclast function. J. Clin. Invest. 107:1137-1144.
36. Boyce, B.F., Aufdemorre, T.B., Garrett, I.R., Yates, A.J.P., and Mundy, G.R. 1989. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology. 125:1142-1150.
37. Smart, E., Ying, Y., Mineo, C., and Anderson, R. 1995. A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc. Natl. Acad. Sci. U. S. A. 92:10104-10108.